The reclassification order runs to eleven pages and contains no cruelty of any kind. It observes that a device which exceeds the biological baseline across its measured domains cannot reasonably be described as restorative, and that restorative coverage is defined by statute as coverage of restoration. It gives operators until the first of the year. The reasoning is clean and, so far as I can follow it, correct on its own terms.
What it does in practice is remove roughly forty million people from medical coverage they have held for most of their lives, and it does so by reclassifying their limbs rather than by touching their entitlement. Nobody has been denied anything. The category simply moved out from under them.
Nadia Cortez was fitted at seven, after a corridor collapse in the winter of 2027 that most readers here will not remember and that she describes with some impatience as the least interesting thing about her. She is forty-eight, a hydrology inspector, and has been through five limbs, each one covered, each one replaced on the clinical schedule without her having to think about it very much. Her Series Nine arrived in 2046. Under the order it is a performance product, so that from January she will pay the tier subscription on it the way an elective pays, out of a blended wage that was not built to carry it.
The obvious remedy is to fit her with something that still qualifies as a prosthesis. I spent a fortnight trying to establish what that would be. The last limb certified as baseline-conformant was the Series Six, which Anatome discontinued in 2045 on the grounds that demand had collapsed, which it had. There is at present no limb in production anywhere in the licensed market that meets the restoration standard, because meeting it would require a manufacturer to deliberately build something worse than what it already knows how to build, and no regulator has asked anyone to.
So the statute now covers a category of device that does not exist. I want to be careful not to present this as a conspiracy, because everything I have seen suggests it is something less deliberate and harder to fix. Each decision in the chain was defensible in isolation. The Crossover was in 2039 while the coverage schedules were written in 2034, and nine years is not a long time for a regulatory instrument to go unrevised.
The downgrade queue at the BioDistrict clinics is the part I did not expect. Several hundred people have asked to be refitted with something slower, on the reasoning that a limb which does less might cost less. The clinics have been explaining that the envelope, not the hardware, determines output, and that a request to be made weaker is administratively a request to move to a lower subscription tier, which is available immediately and which most of them cannot afford either. A specialist at Orchard Road told me she has stopped calling it a downgrade queue in front of patients. She calls it the tier clinic now.
There is a consequence of tier billing that I have found difficult to write down without sounding as though I am reaching for an image. When a subscription lapses the envelope tightens on a published schedule which is graduated rather than abrupt, so that what a lapse produces over about a fortnight is slowness rather than a stop. I have been in this district eleven years. I have started reading it in the corridor at Orchard Road without intending to, in the way one reads a limp or a tremor, and I can now tell with reasonable confidence who is two months behind. I would rather not have learned how to do that.
The Council has opened a consultation, which closes in November and which the disability advocacy networks have already said they will treat as inadequate. Their submission makes a narrower argument than the coverage of it suggests. They are not asking for the Crossover to be undone or for anyone’s limb to be made worse. They are asking that restoration be defined against the person rather than against a population baseline, so that a device restoring Nadia Cortez to the capacity of Nadia Cortez counts as restorative regardless of where that sits on a curve.
It is a good argument and I do not expect it to succeed. A standard defined against the person cannot be priced, which matters a great deal here, because everything downstream of this order is a pricing instrument wearing clinical language.